IP
IndiaPulse

Rays of Belief Limited (MOMSBELIEF)

Micro Cap

Healthcare stocks · Micro cap · NSE

Rays of Belief Limited operates in Hospital, within the Healthcare sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹223.73
+7.69 · +3.56%
Quote20 Sept, 05:22 pm IST
Fundamentals20 Sept 2026 · screener
Score20 Sept, 05:22 pm IST · v4.3-runtime-valuation
Tags20 Sept 2026
Coverage9/14 · 64%
Valuation2026-07-20 · Rf 6.8% · Healthcare P/E 22.0 (n=0)
Data confidence
Verify one data layer
Stock analysis snapshot

Rays of Belief Limited (MOMSBELIEF) share analysis

Rays of Belief Limited is a micro-cap NSE-listed company in Hospital. Its latest recorded share price is ₹223.73. IndiaPulse assigns it a U-Score of 17/100 and classifies its valuation as overvalued.

Current reported fundamentals include P/E of 94.3, ROE of 16.1%, and debt/equity of 0.30. Review these figures alongside the company's growth, cash-flow, balance-sheet and peer evidence below.

Market cap
Rs 468 Cr
P/E
94.3
ROE
16.1%
Debt/equity
0.30
U-Score
17/100

Compare with Chandan Healthcare Ltd. (CHANDAN), Lyka Labs Limited (LYKALABS) and QMS Medical Allied Services Ltd. (QMSMEDI) or open the complete peer comparison.

Investor decision lenses

One read, four checks

75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.

Weak fundamentals, management trust is not scored yet, timing is unclear, and result consistency is still building.

Suggested next step
Research, do not rush
The four lenses are not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
OVERVALUED
17

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Trust
pending

Management reliability not computed yet.

Technical
pending

Technical trend unavailable.

Result consistency
pending

Rolling lens: recent quarterly delivery, not the latest single-result score.

Latest result

Quarterly result analysis pending

No classified quarterly result is available yet. Financial-history charts below may still contain upstream data.

Business & thesis

Growth engines, tailwinds/headwinds, and risk radar from management commentary

Business and thesis

Issuer presentation review pending

Rays of Belief Limited operates in Hospital, within the Healthcare sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed does not yet contain a classified quarter. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Management accountability

What management said, and what results must prove

Technical timing lens

Trend score and candlestick chart

Trend score is pending. The candlestick chart remains available for manual review.

Technical chart

MOMSBELIEFweekly · 3Y · AUTO-0.5%
Latest close ₹223.73 on 2026-09-14
Bar
-0.5%
RSI
-
MACD hist
-
52W pos
51%
2026-09-14O ₹224.96H ₹229.00L ₹213.72C ₹223.73Vol 6.5L sh
₹206.48₹215.00₹223.51₹232.03₹240.5552H52L223.73VolRSIMACD2026-092026-09
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Not enough price history to compute a technical trend read.

Valuation & score drivers

U-Score 17 · OVERVALUED · pillar breakdown, sector model, fair-value anchor

17U-SCORE
OVERVALUED

Fundamental score breakdown

OVERVALUED
Valuation0/30
Growth2/25
Quality7/20
Balance Sheet10/15
Cash Flow0/10
Piotroski
4/9 (+1)
Penalties
-3
Raw sum
17

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

17/100 · OVERVALUED

Positive drivers

  • Balance sheet contributes 10/15 to the score.
  • Quality contributes 7/20 to the score.
  • Growth contributes 2/25 to the score.

Main drags

  • Penalty bucket subtracts 3 points.
  • Fair-value margin of safety is negative at -852.1%.
  • Valuation is weaker at 0/30; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
94.3
PB
EV/EBITDA
28.6
ROE
16.1%
ROCE
FCF Yield
Debt/Equity
0.3
MoS
-852.1%
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 20 Sept 2026
v4.3-runtime-valuation
Final score
17
Previous: 18 (-1)
Verdict
OVERVALUED
Previous: OVERVALUED
Margin of safety
-852.1%
Previous: -852.1%

Score history

One stored score snapshot exists. The trend will become useful after the next score run.

20 Sept 2026
v4.3-runtime-valuation
18

Factor attribution

Quality
7-1
was 8

Modelled fair value

Graham Number
Growth-justified P/E
7.4
Growth-justified Value
₹23.5
-852.1% MoS
PEG

Trust score

Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth

Trust Score

Trust profile pending

Trust asks a simple question: can investors rely on management behaviour and financial delivery? Trust Lite uses promoter alignment, cash conversion, leverage, and result consistency. Full transcript-based claim matching appears after enough documents are ingested.

Not scored

Financials

Full fundamentals table and 10-year revenue / profit / ROE history

Fundamentals

Valuation

P/E
94.30
P/B
EV/EBITDA
28.63
Market Cap
468.00Cr

Profitability

ROE
16.10%
ROCE
ROA
9.75%
Dividend Y

Growth (CAGR)

Revenue 5Y
EPS 5Y
Revenue 3Y
EPS 3Y

Balance Sheet

Debt/Equity
0.30
Interest Coverage
8.03×
Altman Z
9.04
Book Value

Cash Flow

FCF Yield
FCF Positive Y
0/5
OCF
-1.94 Cr
EPS TTM
3.18

Shareholding

Promoter Hold
68.77%
Promoter Pledge
0.00%
Momentum 52W
52%

Financial History

Updated 20/9/2026

Revenue

₹ Cr
Latest: 81.7
081.7Mar 2026: 81.7FY26

Net Profit

₹ Cr
Latest: 5.0
05.0Mar 2026: 5.0FY26

Return on Equity

%
Latest: 16.1
016.1Mar 2026: 16.1%FY26

Peers

Business-comparable names in Healthcare, ranked by similarity

Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.